Navigation Links
ThromboGenics Announces Half Year Results 2008
Date:8/28/2008

r patients.

The first Phase l study showed that TB-403 was safe and well tolerated,

with a pharmacokinetic profile which would allow it to be developed as

a treatment for cancer. TB-403 has moved into a Phase Ib trial. This

study will look at the tolerability, pharmacokinetics and

pharmacodynamics of TB-403 in patients with advanced cancer.

- Microplasmin: Positive results announced in Phase II

clinical trials for ophthalmic indications. Positive results were

reported in ThromboGenics' Phase IIb MIVI III trial in patients with a

number of back of the eye conditions. The trial showed that the most

effective dose of microplasmin studied (125 micro g) was able to

resolve the underlying disease in approximately 30% of patients and

consequently achieved the avoidance of surgical intervention in those

patients.

Further positive six month follow-up results from the Phase IIa MIVI IIT trial, designed to evaluate both the safety and efficacy of microplasmin injection for the treatment of vitreomacular traction, were presented at the Euretina Congress in Vienna, Austria in June.

Investor Highlights

ThromboGenics has continued to work to broaden the Company's shareholder base. In July, ThromboGenics announced the acquisition of an 8% stake in the Company by a group of private investors based in Belgium in a transaction coordinated by Petercam. Their stake was purchased from Biggar Limited, a charitable foundation that is ThromboGenics' largest shareholder. Biggar intends to remain an important shareholder in ThromboGenics for the long term.

Financial Summary

- In the first six months of 2008, revenue amounted to EUR30.3

million. This much higher level of revenue is due to Roche's upfront

payment following the signed co-development deal on TB-403. Operating

expenses were EUR13.0 million in the first half, the majority of which

were due
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
2. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. ThromboGenics N.V. - Business Update
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. ThromboGenics Announces 2007 Full Year Results
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
9. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
10. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
11. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... sophisticated equipment, trained personnel, and detection dogs to ... attacks. A revolutionary new electronic chip with nano-sized ... much easier. , The groundbreaking nanotechnology-inspired sensor, devised ... ,s School of Chemistry and Center for Nanoscience ... Tracense, picks up the scent of explosives molecules ...
(Date:7/24/2014)... Yushan Yan, Distinguished Professor of Engineering at the ... nanomaterials to solve problems in energy engineering, environmental ... focused on zeolites, porous rock with a well-defined, ... size is so precisely decided that zeolites can ... fraction of an angstrom (one-tenth of a nanometer), ...
(Date:7/24/2014)... Research and Markets has announced ... Analytical Instruments Market 2014-2018" report to their offering. ... Genomics is the study of the gene and its ... and functions of proteomes or sets of proteins by ... involves the mapping of genes and DNA sequencing to ...
(Date:7/24/2014)... BRIDGEWATER, N.J. , July 24, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today announces receipt of notice on July ... that the NYSE-MKT has accepted the CorMedix plan ... the NYSE-MKT. As a result, the NYSE-MKT is ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2University of Delaware researcher describes new approach for creating organic zeolites 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... N.J., March 13 Medco Health,Solutions, Inc. (NYSE: ... sell $300,million aggregate principal amount of 6-1/8 percent senior ... amount of 7-1/8 percent,senior notes due March 15, 2018 ... Banc of America Securities LLC and Barclays,Capital Inc. are ...
... Future Generation Treatment from Abbott Shows No Thrombosis, Low ... in Preliminary Clinical Study of Thirty Patients, ABBOTT ... Lancet from ABSORB, the world,s first clinical trial of ... coronary artery,disease, demonstrated no stent thrombosis, no clinically driven ...
... BERKELEY, Calif., March 13 Nile Therapeutics,Inc. (OTC ... and,full year financial results for 2007. Participants may ... the investor relations section of,Nile,s website at ... company,s website until the next quarterly conference call., ...
Cached Biology Technology:Medco Issues $1.5 Billion of Senior Notes 2Medco Issues $1.5 Billion of Senior Notes 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 4Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3
(Date:7/24/2014)... A sake brewery has its own microbial terroir, meaning ... resemble those found in the product, creating the final ... the journal Applied and Environmental Microbiology . This ... census of a sake brewery. , Many sake ... author David A. Mills of the University of California, ...
(Date:7/24/2014)... The University of Texas Health Science Center at Houston ... help Harris County residents whose vision problems cannot be ... corrective lenses, many people with low vision can see ... low vision devices, such as telescopes, magnifiers and electronic ... is using the three-year, $164,645 SightFirst grant from the ...
(Date:7/24/2014)... hotspot of biodiversity and one of the most species ... the world. However, current levels of diversity might be ... an increase in the description of new endemic species ... techniques and availability of samples for DNA analysis. ... molecular and morphological analysis, researchers from the University ...
Breaking Biology News(10 mins):The microbes make the sake brewery 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2A tiny new species of frog from Brazil with a heroic name 2
... imaging to "see" programmed cell loss—the body's normal way ... in early identification of those individuals who are at ... April Journal of Nuclear Medicine. , "Our study indicates ... apoptosis—in heart failure patients using annexin A5 imaging," explained ...
... are alike, they can display a comparable pattern of ... at the Max Planck Institute for Dynamics and Self-Organization ... design networks from neural cells which exhibit a predefined ... assist them in getting closer to understanding which of ...
... genetic and geographic data of the H5N1 avian flu ... They found that multiple strains of the virus originated ... many of the migration routes through which the strains ... strains develop and migrate, health officials can better limit ...
Cached Biology News:Heart failure: Intervention possibilities from imaging programmed cell loss 22 brains -- 1 thought 22 brains -- 1 thought 3UCI scientists reconstruct migration of avian flu virus 2
... high experimental throughput, minimum input of ... 4 up to 16 culture vessels ... users with proven fermentation results when ... fungi or any other microbial application. ...
... Experion system, 100-120 and 220-240 V, is ... steps of gel-based electrophoresis, including some data ... is used for protein analysis (it does ... RNA analysis). The system includes the electrophoresis ...
... in the submicron range are part of ... and control of particle size is important ... can reliably detect the component populations in ... Particle Size Analyzer uses Photon Correlation Spectroscopy ...
... Binding: High, 400 ng IgG/cm 2 ... Interaction: Hydrophobic/Ionic , Performance Certified: Well-to-Well, CV ... Maximum Well Volume: 360 µl , Packaging: ... ,Features, Special optically clear polystyrene formulation , ...
Biology Products: